Survodutide

Synonyms: Survodutide, BI 456906, Glucagon/GLP-1 receptor dual agonist, GCGR/GLP-1R co-agonist

Survodutide is a synthetic peptide engineered as a dual agonist of the glucagon receptor (GCGR) and glucagon-like peptide-1 receptor (GLP-1R). It belongs to a new generation of incretin-based therapeutics designed to address metabolic disorders through simultaneous activation of two complementary pathways. Originally developed by Boehringer Ingelheim, survodutide has drawn significant interest for its potential in obesity and non-alcoholic steatohepatitis (NASH).

Structurally, survodutide is a 29-amino acid peptide with a C-terminal extension and a fatty acid side chain that promotes albumin binding and extends its half-life. This modification allows for once-weekly subcutaneous dosing. The dual agonism leverages GLP-1 receptor activation to suppress appetite and improve glycemic control, while glucagon receptor activation increases energy expenditure and promotes hepatic lipid oxidation, offering a multi-pronged approach to weight management and liver health.

In clinical trials, survodutide has demonstrated robust reductions in body weight and improvements in liver fibrosis markers, positioning it as a promising candidate for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). As the demand for effective therapies grows, survodutide represents a critical tool for researchers and pharmaceutical companies focused on metabolic diseases.

Function

• Dual receptor agonism: Simultaneously activates GCGR and GLP-1R, enhancing metabolic effects.
• Appetite suppression: GLP-1R activation reduces food intake and promotes satiety.
• Increased energy expenditure: GCGR activation stimulates thermogenesis and lipid oxidation.
• Glycemic control: Improves insulin sensitivity and glucose homeostasis.
• Hepatic steatosis reduction: Promotes fat breakdown in the liver, addressing NASH.

Source & Standardization

• Source: Synthetic peptide produced by solid-phase peptide synthesis.
• Standardization: ≥98% purity by HPLC; identity confirmed by mass spectrometry.
• Forms: Lyophilized powder for reconstitution.
• Applications: Research on obesity, diabetes, NASH, and metabolic syndrome.

Specifications

Documentation & Supply

• Monthly capacity: 100 g
• Lead time: 3-5 business days (stock items)
• Documentation: COA, MSDS, TDS, HPLC, MS
• Packaging: Lyophilized powder in sealed vials

Request For Quote

• LyvBio Co., Ltd. — Email: info@lyvbio.com